What is BioCryst Pharmaceuticals's PP&E (net)?

BioCryst Pharmaceuticals (BCRX) reported PP&E (net) of $9.37M in Q1 2026.

How has BioCryst Pharmaceuticals's PP&E (net) changed year-over-year?

BioCryst Pharmaceuticals's PP&E (net) increased by 23.4% year-over-year, from $7.59M to $9.37M.

What is the long-term trend for BioCryst Pharmaceuticals's PP&E (net)?

Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's PP&E (net) has grown at a 4.3% compound annual growth rate (CAGR), from $7.11M to $8.78M.

What does PP&E (net) mean?

Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.

BioCryst Pharmaceuticals BCRX PP&E (Net)

PP&E (Net) at other companies

Ionis PharmaceuticalsIONS

$142.4M+38.4%

Ultragenyx PharmaceuticalRARE

$239M-8.4%

BridgeBio PharmaBBIO

$4.94M-26.2%

Arrowhead ResearchARWR

$374.82M-2.6%

Agios PharmaceuticalsAGIO

$10.57M-4.5%

ALN

Alnylam PharmaceuticalsALNY

$518.26M+3.9%

Other financials

Income statement

See full

Revenue$156.4M+7.5%

Gross profit$151.0M+7.1%

Operating income-$701.6M-3,405%

Net income-$721.8M-2,255,763%

EPS (diluted)-$2.98—

Balance sheet

See full

Cash & equivalents$173.4M+62.2%

Total debt$411.8M+24.7%

Total equity-$553.8M-22.6%

Total assets$465.1M-3.1%

Cash flow

See full

Operating cash flow-$61.8M-125%

CapEx$403.0K+182%

Free cash flow-$62.2M-125%

Valuation

See full

Market cap$2.37B+52.3%

Enterprise value$2.6B+46.7%

P/S2.7×-0.4×

Profitability

See full

Gross margin97.8%+0.8pp

Operating margin-43.1%-49.7pp

Net margin-51.7%-69.7pp

FCF margin35%—

Returns & leverage

See full

Return on equity-882.8%—

Debt / equity0.1×—

Current ratio1.9×-1.0×

Where this comes from

Reported directly by BioCryst Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:PropertyPlantAndEquipmentNet.

The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about BioCryst Pharmaceuticals's pp&e (net).

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is BioCryst Pharmaceuticals's PP&E (net)?: BioCryst Pharmaceuticals (BCRX) reported PP&E (net) of $9.37M in Q1 2026.
How has BioCryst Pharmaceuticals's PP&E (net) changed year-over-year?: BioCryst Pharmaceuticals's PP&E (net) increased by 23.4% year-over-year, from $7.59M to $9.37M.
What is the long-term trend for BioCryst Pharmaceuticals's PP&E (net)?: Over 5 years (2020 to 2025), BioCryst Pharmaceuticals's PP&E (net) has grown at a 4.3% compound annual growth rate (CAGR), from $7.11M to $8.78M.
What does PP&E (net) mean?: Total property, plant, and equipment minus accumulated depreciation — the net book value of all tangible long-lived assets.